Article ; Online: Novel therapies upon failure of HMA plus venetoclax.
Hematology. American Society of Hematology. Education Program
2023 Volume 2023, Issue 1, Page(s) 702–708
Abstract: The efficacy and tolerability of the combination of hypomethylating agents with venetoclax (HMA-VEN) in patients with newly diagnosed acute myeloid leukemia has been a practice-changing milestone in the field. However, treatment failure and relapse ... ...
Abstract | The efficacy and tolerability of the combination of hypomethylating agents with venetoclax (HMA-VEN) in patients with newly diagnosed acute myeloid leukemia has been a practice-changing milestone in the field. However, treatment failure and relapse remain major barriers to prolonged survival. TP53 mutation is a predictor of primary induction failure and portends especially poor outcomes. Prelinical data suggest that VEN resistance stems from these genetic changes, which lead to increases in antiapoptotic proteins such as MCL-1 and BCLXL. For patients who discontinue HMA-VEN for reasons other than disease progression, such as post allotransplantation, infection, and personal preference, rechallenge with HMA-VEN at the time of relapse may be considered. For those who progress on HMA-VEN, clinical trials with novel agents or rational drug combinations are preferred if available. If no trial option is available, fit patients may benefit from intensive chemotherapy. Emerging therapies aim to overcome venetoclax resistance, target interactions that promote leukemogenesis, and harness the immune system to irradicate leukemic blasts and stem cells. |
---|---|
MeSH term(s) | Humans ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Disease Progression ; Leukemia ; Recurrence ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Antineoplastic Combined Chemotherapy Protocols ; Retrospective Studies |
Chemical Substances | venetoclax (N54AIC43PW) ; Bridged Bicyclo Compounds, Heterocyclic |
Language | English |
Publishing date | 2023-12-08 |
Publishing country | United States |
Document type | Journal Article |
ZDB-ID | 2084287-9 |
ISSN | 1520-4383 ; 1520-4391 |
ISSN (online) | 1520-4383 |
ISSN | 1520-4391 |
DOI | 10.1182/hematology.2023000456 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.